Seikagaku Of Tokyo To Submit NDA For Lumbar Disc Hernia Injection In 2011
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Seikagaku plans to submit a new drug application for SI-6603 (chondroitinase) for patients with lumbar disc hernia